ALMS
Alumis Inc.
Alumis (ALMS) Q2 2026 earnings
Published Aug 13, 2026
AI summary
- Revenue $1.66M, down 38% from $2.67M a year ago.
- Alumis reported revenue of $1.66 million for the second quarter of 2026, down from $2.67 million a year ago.
- The company recorded a net loss of $142.2 million for the quarter, compared to a profit in the prior year period.
- Operating expenses included a $41.8 million impairment charge related to the lonigutamab program.
- The company remains on track to submit an FDA application for its psoriasis drug envudeucitinib in Q4 2026.
Results vs analyst consensus
Revenue
Reported
$1.66M
Consensus not captured before release
−38% YoY
EPS
Not reported in this release.
Consensus: Yahoo Finance · Q2 2026
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company recorded a $41.8 million impairment loss on the lonigutamab program and is exploring strategic alternatives.
- The prior year's net income was significantly boosted by a $187.9 million non-operating gain from a merger.
Read original report
Source: Alumis Inc. press release · SEC Form 8-K exhibit 99.1